Triple-negative breast cancer does not respond to targeted breast cancer treatments, which limits treatment to primarily chemotherapy for now.

Datroway significantly improves overall and progression-free survival in metastatic triple-negative breast cancer patients ineligible for immunotherapy. TROPION-Breast02 trial results highlight ...

It may come as no surprise that breast cancer is the most common cancer in women worldwide. In the United States, about 275,000 women are diagnosed with breast cancer each year. Triple-negative breast ...

Trodelvy reduced risk of disease progression or death versus chemotherapy in patients with previously untreated metastatic triple-negative breast cancer. Treatment with Trodelvy (Sacituzumab govitecan ...

Sacituzumab govitecan targets Trop-2 and delivers potent chemo directly to TNBC cells. PARP inhibitors are effective in TNBC patients with BRCA mutations. Immune checkpoint inhibitors benefit patients ...

Research presented by Dr Erik Sahai has shown that early, reversible diversity in tumour cell state can blunt the effect of ...

Living with metastatic triple-negative breast cancer (mTNBC) means facing uncertainty and emotional ups and downs. “Treatment can not only take a physical toll, but also a mental and emotional toll,” ...

When you’re living with metastatic triple-negative breast cancer (mTNBC), the journey is about not only managing the illness, but also navigating the physical and emotional changes that come with ...

An already approved breast cancer drug could bring hope to thousands of UK women who have an aggressive form of breast cancer, new research has found. The study, published in the journal Cancer ...

Characteristics of the tumor microenvironment are likely to contribute to the aggressiveness of triple-negative breast cancer (TNBC) and the extremely poor prognosis of those who suffer it. By ...